#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    KBG syndrome Cardiac failure acute Astrocytoma malignant Neuroendocrine carcinoma metastatic B-cell lymphoma refractory B-cell type acute leukaemia Non-Hodgkin's lymphoma unspecified histology indolent Thrombotic thrombocytopenic purpura Acute lymphocytic leukaemia B-cell small lymphocytic lymphoma recurrent Salivary gland cancer Amyotrophic lateral sclerosis gene carrier Diffuse large B-cell lymphoma refractory Cutaneous T-cell lymphoma Pleural mesothelioma malignant More trials…

    Learn about Rare Diseases

    Fragile X syndrome – Basic Information Ornithine transcarbamoylase deficiency Pemphigoid – Basic Information Proteus syndrome – Diagnostics Chondrosarcoma metastatic – Treatment Progressive supranuclear palsy – Diagnostics Short-bowel syndrome – Basic Information Ehlers-Danlos syndrome Mantle cell lymphoma stage II – Diagnostics Mantle cell lymphoma stage II – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rucaparib Flutafuranol (18F) SP16 Somatropin Lauromacrogol 400 Azelastine Hydrochloride Regn5668 Venglustat Piperacillin Rosnilimab Caspofungin Acetate Mebufotenin Cholesterol Anitocabtagene Autoleucel Cariprazine KETOROLAC TROMETAMOL Amcenestrant GSKVX000000070250 Opevesostat Zalunfiban More therapies…

    Learn about Your Condition

    Rectal cancer stage III Tumour of ampulla of Vater HER2 protein overexpression Lymphocyte adoptive therapy Labour pain Shock Coeliac disease Vulval cancer recurrent Hip arthroplasty Peritoneal dialysis Mitral valve disease Low cardiac output syndrome Diabetic retinopathy Critical illness Rheumatic disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer stage II

  • Study on Pre-Operative Treatment for Breast Cancer Using Nivolumab, Ipilimumab, and Relatlimab for Patients with Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Relatlimab
    • Doxorubicin Hydrochloride
    The Netherlands

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Breast cancer female
    • Breast cancer stage II
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer stage II
    • Breast cancer stage III
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    • Zanidatamab
    Germany Italy Spain

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer male
    • Breast cancer stage I
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Capecitabine
    • Carboplatin
    Austria Belgium France Germany Ireland Spain

  • Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer stage II
    • Breast cancer stage III
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Pertuzumab
    • Trastuzumab
    The Netherlands
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!